Cargando…

Pharmacoeconomic evaluation of costs of rheumatoid arthritis therapy with selected biological treatment

OBJECTIVES: Among autoimmune diseases, rheumatoid arthritis (RA) is the most common chronic inflammatory disease of the joints. Its pathogenesis is still not fully understood, but the gained knowledge has contributed to the development of modern treatment. The introduction of biological therapy for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kowalik, Krzysztof, Węgierska, Małgorzata, Barczyńska, Tacjana, Jeka, Sławomir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2018
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330685/ https://www.ncbi.nlm.nih.gov/pubmed/30647479 http://dx.doi.org/10.5114/reum.2018.80710

Ejemplares similares

Pharmacoeconomic evaluation of treatment effectiveness with selected biologic treatment in rheumatoid arthritis therapy
por: Kowalik, Krzysztof, et al.
Publicado: (2018)

Coexistence of rheumatoid arthritis and ankylosing spondylitis
por: Barczyńska, Tacjana Anna, et al.
Publicado: (2015)

DAS28 score vs. ultrasound examination for assessment of rheumatoid arthritis disease activity: comparison and discussion of pros and cons
por: Barczyńska, Tacjana Anna, et al.
Publicado: (2015)

Efficacy of radiation synovectomy (radiosynovectomy or radiosynoviorthesis) with yttrium-90 in exudative inflammation of synovial membrane of knee joints in patients with rheumatic diseases – preliminary report
por: Zalewska, Joanna, et al.
Publicado: (2016)

Osteoporosis diagnostics in patients with rheumatoid arthritis
por: Węgierska, Małgorzata, et al.
Publicado: (2016)

Ocular involvement in rheumatic diseases
por: Dankiewicz-Fares, Iwona, et al.
Publicado: (2023)

Review of Eight Pharmacoeconomic Studies of the Value of Biologic DMARDs Adalimumab, Etanercept, and Infliximab) in the Management of Rheumatoid Arthritis
por: Doan, Quan V., et al.
Publicado: (2006)

The changing role of ultrasonography examination in patients with rheumatoid arthritis in light of recent studies
por: Dura, Marta, et al.
Publicado: (2020)

Results from Polish Spondyloarthritis Initiative registry (PolSPI) – methodology and data from – the first year of observation
por: Guła, Zofia, et al.
Publicado: (2017)

The role of ultrasonography in monitoring long-standing rheumatoid arthritis: a pilot study
por: Jeka, Sławomir, et al.
Publicado: (2017)

Tocilizumab as a first-line biologic treatment in rheumatoid arthritis patients – the impact of concomitant methotrexate treatment and Rheumatic Disease Comorbidity Index on the clinical response – results from the multicenter observational ACT-POL study
por: Stajszczyk, Marcin, et al.
Publicado: (2022)

Pharmacoeconomic analysis of biologics and methotrexate for rheumatoid arthritis from the standpoint of the number needed to treat concept under the Japanese health insurance system
por: Harigane, Kengo, et al.
Publicado: (2022)

Pharmacoeconomic evaluations in the treatment of actinic keratoses
por: Tolley, Keith, et al.
Publicado: (2017)

Pharmacoeconomic Benefits of Antihypertensive Therapy
por: Gonzalez, Edgar R.
Publicado: (2007)

Polymorphisms within the RANK and RANKL Encoding Genes in Patients with Rheumatoid Arthritis: Association with Disease Progression and Effectiveness of the Biological Treatment
por: Wielińska, Joanna, et al.
Publicado: (2020)

A Pharmacoeconomic Outlook of the Biological Drugs Marketed in India: A Cost Variance Analysis
por: Shinde, Viraj A, et al.
Publicado: (2023)

Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines
por: Boyadzieva, Vladimira V., et al.
Publicado: (2018)

Pharmacoeconomics - Determiniation of the Cost-Effectiveness of Helicobacter Pylori Eradication
por: Curtiss, Frederic R.
Publicado: (2003)

The rheumatoid hand in the light of fluorescence: a diagnostic technique of the future?
por: Żuchowski, Paweł, et al.
Publicado: (2019)

Essentials of pharmacoeconomics
por: Rascati, Karen L.
Publicado: (2014)

Principles of pharmacoeconomics /
Publicado: (1996)

Pharmacoeconomic Evaluations: Guidelines for Drug Purchasers
por: Langley, Paul C., et al.
Publicado: (2020)

Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis
por: Iwaszko, Milena, et al.
Publicado: (2018)

Administration costs of intravenous biologic drugs for rheumatoid arthritis
por: Soini, Erkki J, et al.
Publicado: (2013)

Probing the use of fluorescence spectroscopy as a novel diagnostic tool in patients with rheumatoid arthritis: Applicability in the detection of secondary amyloidosis
por: Jeka, Sławomir, et al.
Publicado: (2012)

Pharmacoeconomic analysis of antibiotic therapy in maxillofacial surgery
por: Orzechowska-Wylęgała, Bogusława, et al.
Publicado: (2017)

The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review
por: Joensuu, Jaana T., et al.
Publicado: (2015)

Assessment of the usefulness of skin autofluorescence as an indicator of disease activity and of the risk of developing diabetes in patients suffering from rheumatoid arthritis
por: Jeka, Sławomir, et al.
Publicado: (2015)

Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology
por: Kucharz, Eugeniusz J., et al.
Publicado: (2018)

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results
por: Zhou, Junwen, et al.
Publicado: (2019)

Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis
por: Buttgereit, Frank, et al.
Publicado: (2010)

Antibiotic pharmacoeconomics: an attempt to find the real cost of hospital antibiotic prescribing.
por: Kerr, J. R., et al.
Publicado: (1993)

Cost of rheumatoid arthritis in a selected population from Argentina in the prebiologic therapy era
por: Catay, Erika, et al.
Publicado: (2012)

Association of MICA-129Met/Val polymorphism with clinical outcome of anti-TNF therapy and MICA serum levels in patients with rheumatoid arthritis
por: Iwaszko, Milena, et al.
Publicado: (2020)

Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis
por: Furer, Victoria, et al.
Publicado: (2023)

Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician
por: Findeisen, Kate E, et al.
Publicado: (2021)

Pharmacoeconomic considerations in the treatment of breast cancer
por: Pallis, Athanasios, et al.
Publicado: (2010)

IL-33 Gene Polymorphisms as Potential Biomarkers of Disease Susceptibility and Response to TNF Inhibitors in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Patients
por: Iwaszko, Milena, et al.
Publicado: (2021)

Should additional value elements be included in cost-effectiveness analysis in pharmacoeconomic evaluation: a novel commentary
por: Sun, Lihua, et al.
Publicado: (2023)

Methotrexate, Cyclosporine A, and Biologics Protect against Atherosclerosis in Rheumatoid Arthritis
por: Kisiel, Bartłomiej, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vgouspgi3adapmtumb7dv09jip